Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
11Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
CAMP4 THERAPEUTICS CORPORATION (CAMP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
20Total relationships
4Distinct source URLs
12High confidence
0.795Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
CAMP4 THERAPEUTICS CORPORATION Suppliers
Ticker
Name
Confidence
Evidence
ARE-MA-REGION-NO-75-LLC
ARE-MA-REGION-NO-75-LLC
92%
the Company entered into a Lease Agreement (the "Watertown Lease") with ARE-MA Region No. 75, LLC ("ARE 75"), an affiliate of ARE 59, for approximately 44,000 rentable square feet of laboratory and o…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
90%
On December 18, 2025, CAMP4 Therapeutics Corporation (the “Company”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC (“ Leerink Partners ”), relatin…
Reciprocal relationship from FULC graph: Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC graph: nce with the agreement, the termination became effective on , which is 120 d…
Reciprocal relationship from OPK graph: ence over the particular investee and whether the particular equity security has a readily determinable fair value. We have determined that our ownership in th…
Reciprocal relationship from OTGA graph: Reciprocal relationship from CAMP graph: Reciprocal relationship from OTGA graph: Reciprocal relationship from CAMP graph: Reciprocal relationship from OTGA g…
CAMP4 THERAPEUTICS CORPORATION Customers
Ticker
Name
Confidence
Evidence
GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-NO-3-LIMIT
GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-NO-3-LIMIT
92%
GSK has agreed to pay the Company a one-time, non-refundable upfront payment of $17.5 million.
FULCRUM
FULCRUM
90%
The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) and concluded that the contract counterparty is a customer.
ty fee qualifies for the royalty constraint exception and does not require an estimate of the future transaction price. The Company did not record any license revenue pursuant to the Fulcrum Agreemen…
Reciprocal relationship from BMRN graph: Reciprocal relationship from CAMP graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from CAMP graph: Reciprocal relationship from BMRN g…
COLLABORATION-AGREEMENTS-BIOMARIN-PHARMACEUTICAL
COLLABORATION-AGREEMENTS-BIOMARIN-PHARMACEUTICAL
85%
ty fee qualifies for the royalty constraint exception and does not require an estimate of the future transaction price. The Company did not record any license revenue pursuant to the Fulcrum Agreemen…
Reciprocal relationship from FULC graph: the Company obtained a worldwide exclusive license to certain intellectual property related to CAMP4's Diamond-Blackfan anemia program
t impact of the remeasurement based on the allocated consideration. The gain was included within general and administrative expense and research and development expense in the consolidated statement …
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
increased stock-based compensation expense and an increase of $0.3 million in professional and consulting fees related to audit and tax costs. These increases were partially offset by a decrease of $…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
increased stock-based compensation expense and an increase of $0.3 million in professional and consulting fees related to audit and tax costs. These increases were partially offset by a decrease of $…
MEDICAL-CENTER-CORPORATION
MEDICAL-CENTER-CORPORATION
62%
t impact of the remeasurement based on the allocated consideration. The gain was included within general and administrative expense and research and development expense in the consolidated statement …
OUT-LICENSE-AGREEMENT-FULCRUM-THERAPEUTICS-INC
OUT-LICENSE-AGREEMENT-FULCRUM-THERAPEUTICS-INC
62%
t impact of the remeasurement based on the allocated consideration. The gain was included within general and administrative expense and research and development expense in the consolidated statement …
CAMP4 THERAPEUTICS CORPORATION Debt Obligations
Instrument
Description
Confidence
Evidence
CAMP-DEBT-8462
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
CAMP-DEBT
Debt stack $2.1M
90%
Market cache reports total debt of $2.1M.
CAMP-DEBT-8461
Warrants outstanding: 3601000
90%
xbrl warrant detail from xbrl 2025-12-31.
CAMP4 THERAPEUTICS CORPORATION Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for CAMP4 THERAPEUTICS CORPORATION.
CAMP4 THERAPEUTICS CORPORATION Ownership
Holder
Name
Confidence
Evidence
CAMP-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 47 tracked holders.
